Government Strengthens Surveillance to Combat Antimicrobial Resistance (AMR)

29 Mar 2025 CW Team

Key Government Initiatives on AMR Surveillance Through NARS-Net National Antimicrobial Resistance Surveillance Network (NARS-Net) is operational across the country, monitoring nine priority pathogens isolated from clinical samples for specific drug-bug combinations.

Annual reports on AMR surveillance data (2017–2023) are available at: NCDC AMR Reports.

ICMR Study on AMR Awareness – The Indian Council of Medical Research (ICMR) has conducted studies in collaboration with AMR surveillance partners to assess public and healthcare professionals' knowledge on AMR.

Public Awareness and Regulatory Measures Red Line Awareness Campaign – Launched by the Ministry of Health and Family Welfare, this campaign urges people not to use medicines marked with a red vertical line (including antibiotics) without a doctor's prescription.

Regulatory Framework – Antibiotics are classified under Schedule H and H1 of the Drugs Rules, 1945, requiring strict caution labelling and sale only with a registered medical practitioner's prescription. The National Treatment Guidelines ensure judicious antibiotic use, while the Guidelines on Infection Prevention and Control aim to reduce healthcare-associated infections and antibiotic misuse.

Mass Awareness Initiatives Multimedia Awareness Materials – Posters, videos, radio jingles on the responsible use of antibiotics, and hand hygiene messages are available in 12 regional languages for dissemination across States and Union Territories.

World Antibiotic Awareness Week (WAAW) – The National Programme on AMR Containment organises annual awareness drives targeting healthcare workers and the general public.

These strategic interventions underline the Government’s commitment to combating AMR, ensuring responsible antibiotic use, and safeguarding public health against the growing threat of drug-resistant infections.

The Government of India has intensified its efforts to tackle Antimicrobial Resistance (AMR) through a comprehensive surveillance network and targeted awareness campaigns. These initiatives aim to monitor resistant pathogens, educate healthcare professionals and the public, and promote the judicious use of antibiotics. Key Government Initiatives on AMR Surveillance Through NARS-Net National Antimicrobial Resistance Surveillance Network (NARS-Net) is operational across the country, monitoring nine priority pathogens isolated from clinical samples for specific drug-bug combinations. Annual reports on AMR surveillance data (2017–2023) are available at: NCDC AMR Reports. ICMR Study on AMR Awareness – The Indian Council of Medical Research (ICMR) has conducted studies in collaboration with AMR surveillance partners to assess public and healthcare professionals' knowledge on AMR. Public Awareness and Regulatory Measures Red Line Awareness Campaign – Launched by the Ministry of Health and Family Welfare, this campaign urges people not to use medicines marked with a red vertical line (including antibiotics) without a doctor's prescription. Regulatory Framework – Antibiotics are classified under Schedule H and H1 of the Drugs Rules, 1945, requiring strict caution labelling and sale only with a registered medical practitioner's prescription. The National Treatment Guidelines ensure judicious antibiotic use, while the Guidelines on Infection Prevention and Control aim to reduce healthcare-associated infections and antibiotic misuse. Mass Awareness Initiatives Multimedia Awareness Materials – Posters, videos, radio jingles on the responsible use of antibiotics, and hand hygiene messages are available in 12 regional languages for dissemination across States and Union Territories. World Antibiotic Awareness Week (WAAW) – The National Programme on AMR Containment organises annual awareness drives targeting healthcare workers and the general public. These strategic interventions underline the Government’s commitment to combating AMR, ensuring responsible antibiotic use, and safeguarding public health against the growing threat of drug-resistant infections.

Infrastructure Transport

06 Feb 2026

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Infrastructure Urban

06 Feb 2026

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Infrastructure Urban

06 Feb 2026

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..